JPS6159289B2 - - Google Patents
Info
- Publication number
- JPS6159289B2 JPS6159289B2 JP5859177A JP5859177A JPS6159289B2 JP S6159289 B2 JPS6159289 B2 JP S6159289B2 JP 5859177 A JP5859177 A JP 5859177A JP 5859177 A JP5859177 A JP 5859177A JP S6159289 B2 JPS6159289 B2 JP S6159289B2
- Authority
- JP
- Japan
- Prior art keywords
- test
- compound
- bromocriptine
- administration
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 15
- 229960002802 bromocriptine Drugs 0.000 claims description 15
- 239000000924 antiasthmatic agent Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 18
- 229960001340 histamine Drugs 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000014181 Bronchial disease Diseases 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229920002055 compound 48/80 Polymers 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000006194 liquid suspension Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010042008 Stereotypy Diseases 0.000 description 2
- 206010044291 Tracheal obstruction Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 230000004006 stereotypic behavior Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2086176 | 1976-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS52143229A JPS52143229A (en) | 1977-11-29 |
JPS6159289B2 true JPS6159289B2 (fr) | 1986-12-16 |
Family
ID=10152990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5859177A Granted JPS52143229A (en) | 1976-05-20 | 1977-05-19 | Antiiasthma agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS52143229A (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4740029B2 (ja) * | 2006-04-28 | 2011-08-03 | 新日本製鐵株式会社 | 床版または覆工板の製造方法 |
-
1977
- 1977-05-19 JP JP5859177A patent/JPS52143229A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS52143229A (en) | 1977-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69431568T2 (de) | Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen | |
KR100196674B1 (ko) | 디페닐부틸-피페라진카르복사미드를 이용한 물질 남용 장애의 치료방법 및 그를 함유하는 약제학적 조성물 | |
KR19990067527A (ko) | 동통의 치료를 위한 에피나스틴의 용도 | |
US5426120A (en) | Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
JP3852621B2 (ja) | 血管内皮細胞機能改善剤 | |
DE68903092T2 (de) | Laktamimide in der behandlung arzneiresistenter protozoeninjektionen. | |
RU2126254C1 (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, и способ лечения | |
US5011841A (en) | Treatment of depression | |
JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン/nmdaレセプターリガンドの用法 | |
JPS6159289B2 (fr) | ||
JPH07215872A (ja) | ベンゾ[g]キノリン類の新規使用 | |
US6117890A (en) | Method for treating bipolar disorder | |
EP1099446B1 (fr) | Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du récepteur NK-1 et un agent antidépressant ou anxiolitique | |
DE69229125T2 (de) | Linderung oder vorbeugung des migräneanfalls mit mitteln zur hemmung der mastzellendegranulation | |
JP2004508272A (ja) | アセチルコリンエンハンサー | |
JPH0569093B2 (fr) | ||
JPS6139287B2 (fr) | ||
US5977121A (en) | Use of moxonidine for the treatment of atherosclerosis | |
CZ27299A3 (cs) | Způsob léčení bipolární afektivní poruchy | |
US6090829A (en) | Method for treating excessive aggression | |
NZ225426A (en) | Anti-arrhythmic pharmaceutical compositions, in unit dosage form, containing 4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinoline | |
US3743746A (en) | Process of treating peptic ulcer with a non-anticholinergic agent | |
WO1998005207A1 (fr) | Procede de traitement d'une agressivite excessive | |
KR920003580B1 (ko) | 동맥경화증 예방 및 치료제 | |
LU85371A1 (fr) | Procede de traitement antiarythmique de classe iii |